Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merav Leiba

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Blood Cells, Molecules & Diseases|April 3, 2017
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patientsMerav Leiba, Sarah Malkiel, Ivan Budnik, et al.
Oncotarget|September 11, 2016
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivoGabriela Rozic, Lena Paukov, Jana Jakubikova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignanciesRaanan Berger, Rinat Rotem-Yehudar, Gideon Slama, et al.
Oncotarget|August 25, 2018
STK405759 as a combination therapy with bortezomib or dexamethasone, in <i>in vitro</i> and <i>in vivo</i> multiple myeloma modelsGabriela Rozic, Lena Paukov, Ziv Cohen, et al.
Leukemia & Lymphoma|March 19, 2024
Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature reviewGilad Itchaki, Osnat Jarhovsky, Jorge J Castillo, et al.
Genes, Chromosomes & Cancer|January 25, 2019
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16)Adrian Duek, Luba Trakhtenbrot, Ninette Amariglio, et al.
Oncoimmunology|August 18, 2025
CyTOF profiling of bone marrow immune dynamics across myeloma stagesDana Cholujova, Gabor Beke, Lubos Klucar, et al.
Acta Haematologica|May 5, 2005
Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisisPia Raanani, Luba Trakhtenbrot, Gideon Rechavi, et al.
Oncotarget|December 20, 2014
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotypeKatia Beider, Hanna Bitner, Merav Leiba, et al.
Cancer Medicine|January 25, 2023
AL amyloidosis clonal plasma cells are regulated by microRNAs and dependent on anti-apoptotic BCL2 family membersHila Fishov, Eli Muchtar, Mali Salmon-Divon, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Blood Cells, Molecules & Diseases|April 3, 2017
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patientsMerav Leiba, Sarah Malkiel, Ivan Budnik, et al.
Oncotarget|September 11, 2016
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivoGabriela Rozic, Lena Paukov, Jana Jakubikova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignanciesRaanan Berger, Rinat Rotem-Yehudar, Gideon Slama, et al.
Oncotarget|August 25, 2018
STK405759 as a combination therapy with bortezomib or dexamethasone, in <i>in vitro</i> and <i>in vivo</i> multiple myeloma modelsGabriela Rozic, Lena Paukov, Ziv Cohen, et al.
Leukemia & Lymphoma|March 19, 2024
Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature reviewGilad Itchaki, Osnat Jarhovsky, Jorge J Castillo, et al.
Genes, Chromosomes & Cancer|January 25, 2019
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16)Adrian Duek, Luba Trakhtenbrot, Ninette Amariglio, et al.
Oncoimmunology|August 18, 2025
CyTOF profiling of bone marrow immune dynamics across myeloma stagesDana Cholujova, Gabor Beke, Lubos Klucar, et al.
Acta Haematologica|May 5, 2005
Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisisPia Raanani, Luba Trakhtenbrot, Gideon Rechavi, et al.
Oncotarget|December 20, 2014
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotypeKatia Beider, Hanna Bitner, Merav Leiba, et al.
Cancer Medicine|January 25, 2023
AL amyloidosis clonal plasma cells are regulated by microRNAs and dependent on anti-apoptotic BCL2 family membersHila Fishov, Eli Muchtar, Mali Salmon-Divon, et al.
Pageof 7